Actavis settles sublingual tablet patent spat with Orexo; FDA releases guidance on injectable packaging;

> Actavis Laboratories ($ACT) reached a settlement agreement on patent infringement litigation filed by Orexo. The suit was filed after Actavis filed for a generic version of Orexo's Abstral sublingual tablet for cancer pain. Under the agreement, Actavis can enter the market in June 2018. More

> The FDA released a draft guidance about injectable meds entitled "Selection of the Appropriate Package Type Terms and Recommendations for Labeling Injectable Medical Products Packaged in Multiple-Dose, Single-Dose, and Single-Patient-Use Containers for Human Use." More

> Ocular Therapeutix ($OCUL) said its intracanalicular depot for allergic conjunctivitis met its primary endpoint in a clinical trial. More

Suggested Articles

Kala Pharma's Eysuvis on Tuesday became the first and only corticosteroid approved to treat short-term signs and symptoms of dry eye disease.

Xeris scored an FDA fast track designation for its diazepam formulation, delivered via autoinjector, to treat acute repetitive seizures.

Armed with microrobots and magnetic fields, Pursue scientists are looking to the future of targeted drug delivery, starting with the colon.